ArticleInternational journal of cancer2012
Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice.
Article in International journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Toll-like receptors: versatile players in tumor.Frontiers in immunology · 2026Review
- The gut microbiome and cancer: from tumorigenesis to therapy.Nature metabolism · 2025Review
- Investigation of Toll-like Receptor-2, -3 and -4 Gene Expressions in Larynx Squamous Cell Carcinoma.Turkish archives of otorhinolaryngology · 2022Article
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges.Frontiers in immunology · 2022Review
- Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.Cell death & disease · 2021Article
- Signal-transducing innate receptors in tumor immunity.Cancer science · 2021Review
- TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer.Frontiers in cell and developmental biology · 2020Review
- Toll-Like Receptor 4 Promotes Th17 Lymphocyte Infiltration Via CCL25/CCR9 in Pathogenesis of Experimental Autoimmune Encephalomyelitis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Article
- Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- The Role of Interleukin-23 in the Early Development of Emphysema in HIV1(+) Smokers.Journal of immunology research · 2016Article
- The Yin and Yang of Toll-like receptors in cancer.Oncogene · 2014Review
- Toll-like receptor mediated regulation of breast cancer: a case of mixed blessings.Frontiers in immunology · 2014Review
- Toll-like receptor-4 modulation for cancer immunotherapy.Frontiers in immunology · 2014Review
- Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages.Immunology and cell biology · 2013Article
- Trial Watch: Toll-like receptor agonists for cancer therapy.Oncoimmunology · 2013Review
- Pubertal high fat diet: effects on mammary cancer development.Breast cancer research : BCR · 2013Article
- Innate immunity and the regulation and mobilization of keratinocyte stem cells: are the old players playing a new game?Experimental dermatology · 2012Review
- Murine Skin Carcinogenesis and the Role of Immune System Dysregulation in the Tumorigenicity of 2-Ethylhexyl Acrylate.Biomedicine hubReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Toll-like receptors (TLRs) activate signals that are critically involved in the initiation of adaptive immune responses and many tumorigenic chemicals have been associated with activation of those pathways. To determine the role of TLR-4 (TLR4) in mammary carcinogenesis, we subjected TLR4 deficient and wild type (WT) mice to oral gavage with carcinogenic polyaromatic hydrocarbon 7,12-dimethylbenz(a)anthracene (DMBA). TLR4 deficient mice developed more tumors relative to the WT mice. T cells of TLR4 deficient mice produced elevated levels of IL-17 and lower levels of IFN-γ relative to WT mice. IL-12 secreted by CD11c(+) cells was higher in WT mice, whereas greater amounts of IL-23 were produced by CD11c(+) cells from TLR4 deficient mice. Moreover, there was higher incidence of regulatory T cells in TLR4 deficient mice than WT mice. Similarly, various markers of angiogenesis [matrix metalloproteinases (MMP)-2 and MMP-9, CD31 and vascular endothelial growth factor] were highly expressed in tumors from TLR4 deficient mice than WT mice. The results of this study indicate that TLR4 plays an important role in the prevention of DMBA induced mouse mammary tumorigenesis and efforts to divert the cell-mediated immune response may, therefore, prove to be beneficial in the prevention of mammary tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.